Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0011849 (diabetes)
 277,896 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The development of the pancreatic B cells in the offspring of normal (N), subdiabetic (SD), manifest diabetic (MD) and insulin-treated diabetic (MDI) rats was studied with the aid of immunocytochemical staining for insulin. Morphometric evaluation of the B-cell volume density and weight was made by point sampling. The offspring were studied on gestational days 20 and 22 and in the newborn state. In the N offspring the weight of the B-cell parenchyma doubled during the last 2 days of gestation. This rapid increase may be ascribed not only to high mitotic activity but also to differentiation of putative percursor cells to B cells. The mild glucose intolerance of the SD mothers had no major effects on the fetal B-cell development. In the MD group both the volume density and the weight of the B cells were considerably lower than in the N and SD groups at all ages studied. Despite prolonged gestation, the weight of the fetal B cells in the MD newborns was not greater than that in the 20-day-old fetuses of the N group. Insulin treatment of the MD mothers restored the fetal B-cell development towards normal. This study indicates that manifest maternal diabetes in the rat retards the development of the fetal B cells. This is in obvious contrast to the corresponding situation in human diabetic pregnancy, in which hyperinsulinism represents a striking feature of diabetic fetopathy. It is suggested that a milder form of maternal glucose intolerance together with the relatively longer gestational period in man, compared with the rat, may create conditions that favour fetal B-cell hyperplasia.
 ...
PMID:Diabetes in pregnancy: growth of the fetal pancreatic B cells in the rat. 676 Sep 8

Although the relationship between the actions of cholesteryl ester transfer protein (CETP) and atherosclerosis is complex, a strong body of evidence suggests that its activity (cholesteryl ester transfer [CET]) is proatherogenic. We have previously shown that CET is increased in IDDM patients receiving conventional subcutaneous insulin treatment and normalized when systemic insulin levels are lowered with intraperitoneal insulin delivery (IP). Since CET has been found by many observers to also be accelerated in NIDDM, we sought to determine whether the same salutary effect could be achieved in insulin-requiring NIDDM men before and 7 months after randomization to an intensive treatment regimen (Rx) of either IP (n = 9) or multiple daily insulin injections (MDI; n = 13). HbA1c improved to the same degree in both groups (MDI group: 9.4 +/- 1.1% pre-Rx vs. 7.2 +/- 0.7% post-Rx [P < 0.001]; IP group: 9.2 +/- 1.3% pre-Rx vs. 7.1 +/- 0.5% post-Rx [P < 0.001]). Compared with pre-Rx levels, plasma triglycerides were not significantly changed by either treatment (MDI group: 136 +/- 80 mg/dl pre-Rx vs. 139 +/- 87 mg/dl post-Rx; IP group: 157 +/- 63 mg/dl pre-Rx vs. 188 +/- 89 mg/dl post-Rx), though an upward trend followed IP. Before randomization, CET estimated with both mass and isotopic assays was greater in the NIDDM subjects than in nondiabetic control subjects (P < 0.001). With improved glycemic control, CE mass transfer declined in both groups, but only reached normal levels in the IP group (MDI group at 2 h: 49.0 +/- 13.7 [mean +/- SD] pg pre-Rx vs. 29.5 +/- 15.3 microg post-Rx [-39.7%, P < 0.01]; IP group at 2 h: 40.8 +/- 23.3 microg pre-Rx vs. 10.9 +/- 6.5 microg post-Rx [-73.2%, P < 0.05]) and remained abnormally increased (P < 0.005) in the subjects receiving MDI. Total lipolytic activity after intensive treatment was unchanged from pretreatment levels, which were similar to those of the reference group. Although directional changes in lipoprotein lipase (LpL) and hepatic triglyceride lipase (HTGL) similar to those found in IDDM after MDI and IP were observed, they were not statistically significant. Thus, while improved glycemic control alone achieved by either MDI or IP reduced the pathological increase in CET in these insulin-treated NIDDM men, normalization was only achieved in those treated with IP. Despite near-normal HbA1c levels, CET remained abnormally increased in NIDDM patients treated rigorously with conventional subcutaneous insulin delivery.
Diabetes 1997 Mar
PMID:Effects of multiple daily insulin injections and intraperitoneal insulin therapy on cholesteryl ester transfer and lipoprotein lipase activities in NIDDM. 903 97

The aim of this study was to investigate the one-year developmental outcome of offspring of mothers with pregestational diabetes mellitus (PGDM). We prospectively evaluated 31 women with PGDM (21 with type 1 DM and 10 with type 2 DM) and 41 nondiabetic controls during pregnancy and for one year follow-up. Data showed that offspring of mothers with PGDM scored lower than controls in all aspects of development--mental, psychomotor, and exploration/orientation. Despite the good metabolic control of the mothers with PGDM, their offpsring showed a less favorable developmental outcome at one year than infants of nondiabetic mothers. MDI score and PDI score were significantly lower in the diabetic group than in the controls (91.04 vs 98.15, p<0.05 and 85.15 vs 95.54, p<0.05, respectively). In addition, the orientation/engagement score was lower in the diabetic group as compared with the nondiabetic group (41.04 vs 45.50, p<0.05). Whereas no significant difference was found between the type 1 and type 2 groups with regard to the MDI score, type 2 infants scored lower on the PDI than infants in the type 1 group (78.1 vs 89.3) but higher on the motor quality score (34.0 vs 31.3). These preliminary findings support the need for ongoing large scale developmental follow-up studies of offspring born to diabetic mothers in order to elucidate whether they have cognitive impairment later in life.
 ...
PMID:Developmental outcome of offspring of pregestational diabetic mothers. 1139 65

Intensive diabetes management can be achieved in adults, adolescents, and children with use of CSII. Compared with MDI, CSII has better insulin pharmacokinetics, less variability in insulin absorption, and decreased risk of hypoglycemia; it also offers patients greater flexibility in lifestyle. Careful adjustment of basal and bolus doses and close follow-up, including patient education, are vital to the success of CSII.
 ...
PMID:Insulin pump therapy in the 21st century. Strategies for successful use in adults, adolescents, and children with diabetes. 1204 Aug 64

This study compared external insulin pump treatment using insulin lispro or insulin aspart with multiple daily injections (MDI; four or more injections per day) using insulin glargine and insulin lispro or insulin aspart. An electronic database was used to retrieve various parameters of glycemic control for 515 adult patients with type 1 diabetes. An insulin pump was used by 216 patients, and 299 patients were taking insulin glargine for at least 6 months. The mean age (approximately 33 years), duration of diabetes (approximately 16 years), and duration of treatment (approximately 12 months) were similar for both the pump and insulin glargine groups. The mean (+/-SEM) A1C values were significantly reduced in both groups from the baseline to the end of the study (7.7 +/- 0.1% to 7.5 +/- 0.1% for the pump group and 8.0 +/- 0.1% to 7.7 +/- 0.1% for the insulin glargine group, P< 0.001) with similar weight gain (P> 0.05) in both groups. The insulin glargine group significantly reduced basal insulin intake at follow-up. The premeal boluses were similar throughout the study for both groups. The subjects reporting severe hypoglycemic episodes were similar in the two groups; however, there were 12 cases of diabetic ketoacidosis reported in the pump group and none in the insulin glargine group. Patients with type 1 diabetes can achieve similar glycemic control using insulin glargine with premeal insulin lispro or by using an external infusion pump with insulin lispro or insulin aspart. However, costs and episodes of diabetic ketoacidosis are significantly higher for insulin pump users.
Diabetes Technol Ther 2004 Feb
PMID:Glycemic parameters with multiple daily injections using insulin glargine versus insulin pump. 1500 Jul 65

We examined quality-of-life (QOL) of patients with a prospective comparison of multiple daily insulin injections therapy (16 patients in MDI group) and continuous subcutaneous insulin infusion therapy (12 patients in CSII group) using insulin lispro (LP), which was switched from short-acting insulin on the basis of a questionnaire about insulin-therapy-related QOL measure (ITR-QOL). The overall score of ITR-QOL before using LP in the CSII group was significantly higher (P<0.02) than the MDI group. In four subscales of ITR-QOL, the scores of social and daily activities and of therapy-related feelings in the CSII group were significantly higher (P<0.02) than those in the MDI group, respectively, while there was no significant difference in the score of physical function between the two groups. Three months after using LP, the score of daily activities in the MDI group was significantly higher (P<0.02) than that before using LP, while there were no significant differences in other scores of the two groups. There were no significant differences in HbA1c between two groups before and after using LP. The frequency of hypoglycemic events in the MDI group before using LP was higher than that in the CSII group and decreased after using LP. These results show that QOL of patients treated by CSII is superior to that treated by MDI and demonstrate that insulin lispro has a more beneficial effect on daily activities in patients treated by MDI than short-acting insulin.
Diabetes Res Clin Pract 2004 Apr
PMID:A quality-of-life assessment of intensive insulin therapy using insulin lispro switched from short-acting insulin and measured by an ITR-QOL questionnaire: a prospective comparison of multiple daily insulin injections and continuous subcutaneous insulin infusion. 1503 23

CSII is a feasible, safe and well-accepted mode of therapy for many children with type 1 diabetes. For a significant number of patients and parents, it serves as a much easier means of coping with the huge daily burden of diabetes. Therefore, we believe that both CSII and MDI should be made available to the diabetic team and the patients to better tailor therapy, improve satisfaction and decrease the fear of hypoglycemia.
 ...
PMID:Why pumps? Continuous subcutaneous insulin infusion for children and adolescents with type 1 diabetes. 1515 65

Intensive insulin therapy aiming at normoglycemia in order to prevent long-term complications is not questionable for the management of type 1 diabetes mellitus nowadays. The gold standard mode of insulin therapy in this view is CSII using fast-acting analogues. Whether this reference method can be challenged by MDI using recently available long- and fast-acting analogues remains an open question. Use of fast-acting analogues provides similar benefits on post-meal glucose control either by MDI or by CSII. Long-acting analogues glargine and detemir have shown better effectiveness on basal blood glucose control, including improved stability and reduced occurrence of hypoglycemic episodes, than NPH and ultralente. Reported comparisons between CSII and MDI using glargine have been limited until now. While some of them have shown that CSII allowed both lower HbA1(c) and incidence of hypoglycemia, similar effects have been obtained in other experiences. From present data, it appears that CSII remains the most effective mode of intensive insulin therapy although it may be challenged in patients with stable basal insulin needs. Nevertheless, individual factors seem to be decisional in the choice between CSII and MDI using long-acting analogues, among which patient ability and will to use an insulin pump are critical.
Diabetes Metab 2005 Sep
PMID:Intensive insulin therapy today: 'basal-bolus' using multiple daily injections or CSII? 1638 97

Continuous diabetes education for children, adolescents and their parents are widely accepted as an integral part of every type 1 diabetes therapy. Especially in paediatric diabetes care age-appropriate, demand-oriented and individualized practical information and skills training are mandatory for achieving good metabolic control and psychosocial well-being. A paediatric multidisciplinary diabetes team experienced in an intensified insulin therapy with a differential substitution of prandial and basal insulin needs (MDI or CSII) and in child psychology is required to initiate and maintain lifelong diabetes self-management. In Germany an education programme for children aged 6-12 years and another programme for adolescents and young adults have previously been evaluated in multicenter studies. Programmes were considered with respect to applicability, acceptance by target groups and efficacy (knowledge, competence, quality of life and glycaemic control). Furthermore, a programme specifically designed for parents of children affected was evaluated. Contents, modular structures, developmental psychological background and didactic concepts of all above mentioned programmes are presented in detail. Apart from teaching insulin therapy according to current guidelines special emphasis is laid on translating this knowledge into everyday self-management behaviour. In addition, emotional coping with the chronic disease and its psychosocial consequences is supported. In the context of the Disease-Management-Program for Type 1 Diabetes in Germany these programmes for young people were certified and reimbursed nationwide by health insurances.
Pediatr Diabetes 2007 Oct
PMID:Prerequisites for age-appropriate education in type 1 diabetes: a model programme for paediatric diabetes education in Germany. 1772 87

The study assessed 3.5-year treatment with continuous subcutaneous insulin infusion (CSII) in well-controlled children with duration of type 1 diabetes mellitus longer than 1 year. Following groups were observed: the CSII group-40 children and the multiple injections (MDI) group-36 patients (age-matched, the mean of 6.5+/-2.1 and 7.1+/-1.8 years, respectively). At the onset of the follow-up both groups were comparable in age, HbA1c, daily insulin requirement (DIR), body weight, height and BMI. They were followed from the start, and every 6 months in relation to DIR, HbA1c, acute complications (DKA, hypoglycaemia) and physical development. Mean HbA1c and DIR for the whole study period were lower in the CSII versus MDI group (6.90+/-0.54 vs 7.22%+/-0.16 and 0.75+/-0.16 vs 0.88+/-0.13 U/kg/d; p<0.05). HbA1c was lower in the CSII versus MDI group in months 6 and 42 (6.95 vs 7.29%, and 6.91 vs 7.43%, respectively; p<0.05). DIR was significantly lower at most intervals in the CSII group. No significant differences regarding number of complications and anthropometry were found. CSII allows for near-normal metabolic control and lower insulin requirement comparing to the MDI method. CSII is safe treatment, assuring harmonious child's development.
Diabetes Res Clin Pract 2009 Aug
PMID:Prospective assessment of continuous subcutaneous insulin infusion therapy in young children with type 1 diabetes. 1953 92


1 2 3 Next >>